Three questions to Prof. Gottfried Baier
1. New immunotherapeutic drugs such as CAR-T cells can benefit patients with certain blood cancers such as leukemia, lymphoma and multiple myeloma. What are the main reasons that the use...
December 18, 2023
No Comments
Press release: invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
• Preclinical study will be conducted by Dr. David Reardon’s research group • Immune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer Vienna, Austria and Boston,…
November 10, 2023
No Comments
Press release: invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial…
September 5, 2023
No Comments
invIOs’s EPiC cell therapy platform to progress development of novel CAR-T cell approach against lung cancer with Medical University of Innsbruck
invIOs is teaming up with the Medical University of Innsbruck on a new project to investigate the potential of an innovative CAR-T cell therapy approach to treat aggressive lung tumors....
July 5, 2023
No Comments
Press release: invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indications Treatment with INV501 significantly inhibits tumor growth, extends survival and increases cure...
June 16, 2023
No Comments
Lessons from the clinic: Checkpoint blockade, biomarkers, and the future of individualized solid tumor treatments
We were privileged to welcome Professor Christoph Zielinski as our latest speaker in the invIOs Innovation Lectures. One of Europe's most distinguished medical oncologists, Professor Zielinski shared with us insights...
June 2, 2023
No Comments
Press release: invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours Data...
April 18, 2023
No Comments
Meet invIOs’s new Scientific Advisory Board
Today we're unveiling our new Scientific Advisory Board (SAB), which brings together five leading European cancer experts to help fast-forward our growth. The SAB is a multi-disciplinary formation with cross-cutting knowledge...
February 24, 2023
No Comments
